Stock Ratings | Craig-Hallum initiated coverage of PepGen (PEPG) with a "buy" rating and a price target of $11, representing a potential upside of 591.82%.
CAMP4 Therapeutics Corporation CAMP | 0.00 | |
Rhythm Pharmaceuticals, Inc. RYTM | 0.00 | |
TripAdvisor, Inc. TRIP | 0.00 | |
PepGen Inc. PEPG | 0.00 | |
Context Therapeutics, Inc. CNTX | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
JP Morgan: Upgrades Camp4 Therapeutics ( CAMP4 Therapeutics Corporation(CAMP.US) ) stock to "overweight", raising its price target from $5 to $9.
Canaccord Genuity maintains its "Buy" rating on Rhythm Pharmaceuticals ( Rhythm Pharmaceuticals, Inc.(RYTM.US) ), raising its price target from $143 to $151.
Wedbush: Maintaining its "Outperform Market" rating for TripAdvisor ( TripAdvisor, Inc.(TRIP.US) ), while raising its price target from $19 to $20.
Craig-Hallum: Initial rating for PepGen ( PepGen Inc.(PEPG.US) ) stock at "buy", with a target price of $11.
Maxim Group: Maintaining the "Buy" rating for Context Therapeutics ( Context Therapeutics, Inc.(CNTX.US) ), while lowering the target price from $8 to $4.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| CAMP4 Therapeutics Corporation(CAMP.US) | to lift | $9.0 | $4.13 | 117.92% | JP Morgan |
| Rhythm Pharmaceuticals, Inc.(RYTM.US) | to lift | $151.0 | $89.72 | 68.3% | Canaccord Genuity |
| TripAdvisor, Inc.(TRIP.US) | to lift | $20.0 | $12.81 | 56.13% | Wedbush |
| Patterson-UTI Energy, Inc.(PTEN.US) | to lift | $15.0 | $10.35 | 44.93% | Stifel |
| Dynatrace Holdings(DT.US) | to lift | $60.0 | $41.46 | 44.72% | UBS |
| PepGen Inc.(PEPG.US) | Initial classification | $11.0 | $1.59 | 591.82% | Craig-Hallum |
| Context Therapeutics, Inc.(CNTX.US) | cut | $4.0 | $0.6503 | 515.1% | Maxim Group |
| Neumora Therapeutic(NMRA.US) | cut | $7.0 | $1.56 | 348.72% | HC Wainwright & Co. |
| Neumora Therapeutic(NMRA.US) | cut | $5.0 | $1.56 | 220.51% | Needham |
| DOMO, INC.(DOMO.US) | cut | $5.0 | $2.05 | 143.9% | Cantor Fitzgerald |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Mizuho: Maintaining a "neutral" rating on Amgen Amgen Inc.(AMGN.US) ) stock, while raising the price target from $295 to $303.
Stephens & Co.: Maintaining Covetrus ( Commvault Systems, Inc.(CVLT.US) ) rating at "overweight", while raising the target price from $135 to $155.
HC Wainwright & Co.: Maintaining a "Buy" rating on Krystal Biotech ( Krystal Biotech, Inc.(KRYS.US) ), while raising its price target from $310 to $361.
Hovde Group: Upgraded its rating on RBB Bancorp ( RBB Bancorp(RBB.US) ) to "Outperform," raising its price target from $26 to $29.
First Coverage
Raymond James: Initial rating for Aktis Oncology ( Aktis Oncology, Inc.(AKTS.US) ) at "Strong Buy", with a price target of $40.
Craig-Hallum: Initial rating for PepGen ( PepGen Inc.(PEPG.US) ) stock at "buy", with a target price of $11.
DA Davidson: Initial rating for Watsco Watsco, Inc.(WSO.US) ) stock at "neutral", with a price target of $385.
reduction
B of A Securities: Hudson Pacific Properties ( Hudson Pacific Properties, Inc.(HPP.US) ) downgraded its rating to "underperforming the market" while maintaining its price target at $14.
Evercore ISI Group: Downgraded Roku ( Roku, Inc. Class A(ROKU.US) ) stock rating to "Market Match," with a price target cut from $185 to $160.
RBC Capital: Maintaining its rating on Whirlpool ( Whirlpool Corporation(WHR.US) ) at "Underperforming the Market", while lowering its price target from $32 to $30.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.